Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences

Margolese, Howard C.; Malchy, Leslie; Negrete, Juan Carlos; Tempier, Raymond; Gill, Kathryn

doi:10.1016/s0920-9964(02)00523-6

Cited by 235 publications

(158 citation statements)

References 55 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…This figure falls into the mid-range of previous findings in the UK where widely varying estimates ranging from two to 68% in MHS and four to 83% in DAS were reported [22-23, 31, 36, 59-60]. Similarly, our findings fit well with recent non-UK studies, which reported prevalence rates ranging from six to 78% in the US [61][62][63], 34 to 51% in Norway [7], 14 to 45% in Canada [6], 29% to 43% in Germany [64] and 27 to 49% in Spain [65] across different treatment settings.…”

Section: Discussionsupporting

confidence: 91%

Treatment approaches for dual diagnosis clients in England

Schulte

Meier

Stirling

et al. 2008

Drug and Alcohol Review

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Treatment approaches for dual diagnosis clients in England

Schulte

Meier

Stirling

et al. 2008

Drug and Alcohol Review

View full text Add to dashboard Cite

show abstract

“…Both schizophrenia patients and their unaffected siblings have been reported to have increased substance use compared to the general population (68,69). It is therefore plausible that some of the structural abnormalities observed in this study might have been influenced by substance use.…”

Section: Discussionmentioning

confidence: 72%

“…Notably, prominent correlations were not found between the neuroanatomical measures and current severity of psychopathology, except for a relationship between a schizophrenia-like caudate shape and thought disorganization. Because psychosis severity often fluctuates within a short period, it may be difficult to correlate the current severity of such pathology with neuroanatomical measures (68,66). Rather, structural changes may be more closely related to lifetime measures of psychopathology severity.…”

mentioning

confidence: 99%

Basal Ganglia Shape Abnormalities in the Unaffected Siblings of Schizophrenia Patients

Mamah¹,

Harms²,

Wang³

et al. 2008

Biological Psychiatry

View full text Add to dashboard Cite

Objective-Abnormalities of basal ganglia structure in schizophrenia have been attributed to the effects of antipsychotic drugs. Our aim was to test the hypothesis that abnormalities of basal ganglia structure are intrinsic features of schizophrenia, by assessing basal ganglia volume and shape in the unaffected siblings of schizophrenia subjects.Method-The study involved 25 pairs of schizophrenia subjects and their unaffected siblings and 40 pairs of healthy controls and their siblings. Large deformation, high-dimensional brain mapping was used to obtain surface representations of the caudate, putamen, and globus pallidus. Surfaces were derived from transformations of anatomical templates and shapes were analyzed using reduceddimensional measures of surface variability (i.e. principal components and canonical analysis). Canonical functions were derived using schizophrenia and control groups, and were then used to compare shapes in the sibling groups. To visualize shape differences, maps of the estimated surface displacement between groups were created.Results-In the caudate, putamen and globus pallidus, the degree of shape abnormality observed in the siblings of the schizophrenia subjects was intermediate between the schizophrenia subjects and the controls. In the schizophrenia subjects, significant correlations were observed between measures of caudate, putamen and globus pallidus structure and the selected measures of lifetime psychopathology.Conclusions-Attenuated abnormalities of basal ganglia structure are present in the unaffected siblings of schizophrenia subjects. This finding implies that basal ganglia structural abnormalities observed in subjects with schizophrenia are at least in part an intrinsic feature of the illness. KeywordsSchizophrenia; Siblings; Basal Ganglia; Caudate; Putamen; Globus Pallidus Corresponding Author: Daniel Mamah, M.D., M.P.E. Department of Psychiatry (Box 8134), Washington University School of Medicine, 660 S. Euclid, St. Louis, MO 63110, (314) 747-2160, Fax: (314) 747-2182, E-mail: mamahd@psychiatry.wustl.edu. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Evidence from family, twin and adoption studies suggest that genetic factors play an important role in the pathogenesis of schizophrenia (1,2). Consistent with the involvement of genetic factors in schizophrenia, cognitive (3,4), neurologic (5,6) and neurobiological (7,8) abnormalities have been found in the unaffected relatives of schizophrenia subjects, generally in attenuated form. NIH Public AccessA number of lines of research suggest that basal ganglia abnormalities mi...

show abstract

“…Addiction to tobacco, alcohol or drugs is frequently a co‐morbidity of other psychiatric disorders, including schizophrenia (SCZ) and bipolar disorder (BPD) (Cerullo & Strakowski 2007; Margolese et al 2004). The high rate of smoking among SCZ patients is well known, and increased rates of substance use disorders and smoking are observed among their first‐degree relatives (Smith et al 2008).…”

Section: Introductionmentioning

confidence: 99%

Polygenic risk scores for schizophrenia and bipolar disorder associate with addiction

et al. 2017

View full text Add to dashboard Cite

We use polygenic risk scores (PRSs) for schizophrenia (SCZ) and bipolar disorder (BPD) to predict smoking, and addiction to nicotine, alcohol or drugs in individuals not diagnosed with psychotic disorders. Using PRSs for 144 609 subjects, including 10 036 individuals admitted for in‐patient addiction treatment and 35 754 smokers, we find that diagnoses of various substance use disorders and smoking associate strongly with PRSs for SCZ (P = 5.3 × 10−50–1.4 × 10−6) and BPD (P = 1.7 × 10−9–1.9 × 10−3), showing shared genetic etiology between psychosis and addiction. Using standardized scores for SCZ and BPD scaled to a unit increase doubling the risk of the corresponding disorder, the odds ratios for alcohol and substance use disorders range from 1.19 to 1.31 for the SCZ‐PRS, and from 1.07 to 1.29 for the BPD‐PRS. Furthermore, we show that as regular smoking becomes more stigmatized and less prevalent, these biological risk factors gain importance as determinants of the behavior.

show abstract

Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences

Cited by 235 publications

References 55 publications

Treatment approaches for dual diagnosis clients in England

Treatment approaches for dual diagnosis clients in England

Basal Ganglia Shape Abnormalities in the Unaffected Siblings of Schizophrenia Patients

Polygenic risk scores for schizophrenia and bipolar disorder associate with addiction

Contact Info

Product

Resources

About